2025 Q3 -tulosraportti
122 päivää sitten
‧1 t 2 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
125 895
Myynti
Määrä
128 296
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 386 | - | - | ||
| 917 | - | - | ||
| 74 | - | - | ||
| 115 | - | - | ||
| 50 | - | - |
Ylin
187,5VWAP
Alin
181,6VaihtoMäärä
53,5 290 725
VWAP
Ylin
187,5Alin
181,6VaihtoMäärä
53,5 290 725
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 24.2. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 15.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 24.10.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
3 päivää sitten3 päivää sittenTuesday will be a very interesting day 📈🙏
17.2. · Muokattu17.2. · MuokattuBeen thinking adding bonesupport after recent crash. Any insights to bonesupports moat, redeye says 5-7 years but what about elute EP granules + tobramycin antibiotics which was set to be completed end 2025? If approved it takes 1-2 years to get things rolling. Those seem to compete with each other as elutes triam addresses athe antibiotics part. Clinicialtrials.gov ID NCT05361941. Not that familiar with the space so insights would be appreciated.
·16.2.I, along with most analysts, find it difficult to understand the share price decline. (See recommendations) The arguments against Bonex's share price are mainly two: - The dollar weakens and results in SEK affect the profit. - High P/E ratio, i.e., 77, is frightening. -When it comes to the dollar weakening, the biggest effect is probably over. Carnegie, for example, believes that the krona will stabilize at this level. Regardless of whether the dollar continues to fall slightly, it will have little impact when you have over 90% margin. Arguments in favor of Bonex include: - High P/E ratio is expected to go from 77 to 37 by 2026. The reason is continued margin expansion and strong growth. EPS is expected to practically double. The advantages for Bonex are many. Here are a few: - Bonex is unique with its product and knowledge, as well as a network of hospitals already trained on the base product. - In 2026, positive news is expected, and doctors are now being trained to use the new products on knees, hips, and spines, in addition to arms and legs. These markets are enormously large, and this new technology where Cerament is transformed into the body's own bone. - Cerament in combination with low-eluting antibiotics both eliminates infections and also reduces the risk of antibiotic resistance, which is a gigantic threat for the future. - The proportion of amputations due to infections disappears. - Analysts estimate that no competitor can emerge within 5-7 years. - Reimbursements in the USA increase the contribution for operations with Bonex products by 50 kkr this year. - Hospitals improve patient safety and shorten time, i.e., save money and can help more patients, thereby further increasing profitability. - A growth of 25-35% per year is expected for the next 5 years, while the EBIT margin increases. (39.7% 2025) I will stay invested for a long time.
·2 päivää sittenA thought I've had is if anyone believes that Selin's 9 % stake is leveraged and risks coming back onto the market again? Would that perhaps push down the share price? Otherwise, I agree with you, I find no reason for the short positions, but they are now so large, so for that reason one believes they know something we don't :-(. How else does one dare to take such a large risk in relation to analysts' target prices. I have owned them for 8 years and am not selling either.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
122 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 3 päivää sitten3 päivää sittenTuesday will be a very interesting day 📈🙏
- 17.2. · Muokattu17.2. · MuokattuBeen thinking adding bonesupport after recent crash. Any insights to bonesupports moat, redeye says 5-7 years but what about elute EP granules + tobramycin antibiotics which was set to be completed end 2025? If approved it takes 1-2 years to get things rolling. Those seem to compete with each other as elutes triam addresses athe antibiotics part. Clinicialtrials.gov ID NCT05361941. Not that familiar with the space so insights would be appreciated.
- ·16.2.I, along with most analysts, find it difficult to understand the share price decline. (See recommendations) The arguments against Bonex's share price are mainly two: - The dollar weakens and results in SEK affect the profit. - High P/E ratio, i.e., 77, is frightening. -When it comes to the dollar weakening, the biggest effect is probably over. Carnegie, for example, believes that the krona will stabilize at this level. Regardless of whether the dollar continues to fall slightly, it will have little impact when you have over 90% margin. Arguments in favor of Bonex include: - High P/E ratio is expected to go from 77 to 37 by 2026. The reason is continued margin expansion and strong growth. EPS is expected to practically double. The advantages for Bonex are many. Here are a few: - Bonex is unique with its product and knowledge, as well as a network of hospitals already trained on the base product. - In 2026, positive news is expected, and doctors are now being trained to use the new products on knees, hips, and spines, in addition to arms and legs. These markets are enormously large, and this new technology where Cerament is transformed into the body's own bone. - Cerament in combination with low-eluting antibiotics both eliminates infections and also reduces the risk of antibiotic resistance, which is a gigantic threat for the future. - The proportion of amputations due to infections disappears. - Analysts estimate that no competitor can emerge within 5-7 years. - Reimbursements in the USA increase the contribution for operations with Bonex products by 50 kkr this year. - Hospitals improve patient safety and shorten time, i.e., save money and can help more patients, thereby further increasing profitability. - A growth of 25-35% per year is expected for the next 5 years, while the EBIT margin increases. (39.7% 2025) I will stay invested for a long time.·2 päivää sittenA thought I've had is if anyone believes that Selin's 9 % stake is leveraged and risks coming back onto the market again? Would that perhaps push down the share price? Otherwise, I agree with you, I find no reason for the short positions, but they are now so large, so for that reason one believes they know something we don't :-(. How else does one dare to take such a large risk in relation to analysts' target prices. I have owned them for 8 years and am not selling either.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
125 895
Myynti
Määrä
128 296
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 386 | - | - | ||
| 917 | - | - | ||
| 74 | - | - | ||
| 115 | - | - | ||
| 50 | - | - |
Ylin
187,5VWAP
Alin
181,6VaihtoMäärä
53,5 290 725
VWAP
Ylin
187,5Alin
181,6VaihtoMäärä
53,5 290 725
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 24.2. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 15.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 24.10.2024 |
2025 Q3 -tulosraportti
122 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 24.2. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 15.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 24.10.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 3 päivää sitten3 päivää sittenTuesday will be a very interesting day 📈🙏
- 17.2. · Muokattu17.2. · MuokattuBeen thinking adding bonesupport after recent crash. Any insights to bonesupports moat, redeye says 5-7 years but what about elute EP granules + tobramycin antibiotics which was set to be completed end 2025? If approved it takes 1-2 years to get things rolling. Those seem to compete with each other as elutes triam addresses athe antibiotics part. Clinicialtrials.gov ID NCT05361941. Not that familiar with the space so insights would be appreciated.
- ·16.2.I, along with most analysts, find it difficult to understand the share price decline. (See recommendations) The arguments against Bonex's share price are mainly two: - The dollar weakens and results in SEK affect the profit. - High P/E ratio, i.e., 77, is frightening. -When it comes to the dollar weakening, the biggest effect is probably over. Carnegie, for example, believes that the krona will stabilize at this level. Regardless of whether the dollar continues to fall slightly, it will have little impact when you have over 90% margin. Arguments in favor of Bonex include: - High P/E ratio is expected to go from 77 to 37 by 2026. The reason is continued margin expansion and strong growth. EPS is expected to practically double. The advantages for Bonex are many. Here are a few: - Bonex is unique with its product and knowledge, as well as a network of hospitals already trained on the base product. - In 2026, positive news is expected, and doctors are now being trained to use the new products on knees, hips, and spines, in addition to arms and legs. These markets are enormously large, and this new technology where Cerament is transformed into the body's own bone. - Cerament in combination with low-eluting antibiotics both eliminates infections and also reduces the risk of antibiotic resistance, which is a gigantic threat for the future. - The proportion of amputations due to infections disappears. - Analysts estimate that no competitor can emerge within 5-7 years. - Reimbursements in the USA increase the contribution for operations with Bonex products by 50 kkr this year. - Hospitals improve patient safety and shorten time, i.e., save money and can help more patients, thereby further increasing profitability. - A growth of 25-35% per year is expected for the next 5 years, while the EBIT margin increases. (39.7% 2025) I will stay invested for a long time.·2 päivää sittenA thought I've had is if anyone believes that Selin's 9 % stake is leveraged and risks coming back onto the market again? Would that perhaps push down the share price? Otherwise, I agree with you, I find no reason for the short positions, but they are now so large, so for that reason one believes they know something we don't :-(. How else does one dare to take such a large risk in relation to analysts' target prices. I have owned them for 8 years and am not selling either.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
125 895
Myynti
Määrä
128 296
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 386 | - | - | ||
| 917 | - | - | ||
| 74 | - | - | ||
| 115 | - | - | ||
| 50 | - | - |
Ylin
187,5VWAP
Alin
181,6VaihtoMäärä
53,5 290 725
VWAP
Ylin
187,5Alin
181,6VaihtoMäärä
53,5 290 725
Välittäjätilasto
Dataa ei löytynyt